August 6, 2019 / 10:20 PM / 12 days ago

BRIEF-Novartis Says It Stands Behind Its Zolgensma Gene Therapy

Aug 6 (Reuters) - Novartis AG:

* NOVARTIS AG SAYS IT STANDS BEHIND ZOLGENSMA FOR TREATMENT OF CHILDREN LESS THAN 2 YEARS OF AGE WITH SPINAL MUSCULAR ATROPHY

* NOVARTIS AG SAYS IT IS "FULLY CONFIDENT" IN THE SAFETY, QUALITY AND EFFICACY OF ZOLGENSMA

* NOVARTIS - TO CONTINUE TO WORK IN CLOSE COOPERATION WITH U.S. FDA TO APPROPRIATELY UPDATE SUBMISSION, ADDRESS ANY QUALITY GAPS IDENTIFIED IN ZOLGENSMA

* NOVARTIS SAYS DO NOT EXPECT FDA STATEMENT TO IMPACT TIMING OF ONGOING ZOLGENSMA REGULATORY FILINGS AND DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below